ENGLEWOOD CLIFFS, NJ, April 20, 2021 / PRNewswire / – Enzychem Lifesciences (KOSDAQ: 183490), a biopharmaceutical company developing innovative drugs to improve the lives of patients with cancer and inflammatory diseases, announced today that it is ready to partner with the Chemical Countermeasures Research Program (CCRP) Selected at the National Institute for Allergies and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), the Biomedical Agency for Advanced Research and Development (BARDA) of the Department of Health and Human Services and Battelle to evaluate the therapeutic effectiveness of EC -18 As a Medical Countermeasure (MCM) to inhalation sulfur mustard exposure.
Sulfur mustard (SM) is a powerful bifunctional, vesicating, alkylating chemical warfare agent known to cause injury to the respiratory tract, eyes, skin, and multiple organs. SM poisoning primarily affects the lungs and can result in lung injury leading to acute lung injury, acute respiratory distress syndrome, bronchiolitis obliterans, fibrosis, and subsequent related infections.
Enzychem’s lead compound, EC-18, is an immunomodulator that rapidly resolves inflammation and restores immune homeostasis by accelerating intracellular trafficking in pattern recognition receptor-bound pathogenic invaders or endogenous hazard signals. Because of its unique mechanism of action, EC-18 can be an effective candidate for reducing SM-induced tissue injury by limiting over-recruitment of neutrophils and rapidly eliminating extraneous and hazardous signals.
“Exposure to SM results in debilitating blisters and serious injury to the eyes and lungs, which in some cases can be fatal,” he said DoHyun Cho, COO of Enzychem Lifesciences. “We are excited to be working again with NIAID / NIH, CCRP, BARDA and Battelle to further evaluate the effectiveness of EC-18 as a potential MCM against SM when no effective treatment modalities are currently available.”
This project is partially funded with federal funds from BARDA and NIAID under an Interagency Agreement (IAA AOD20007-001-00000) and contract number HHSO100201500004I.
About Enzychem Lifesciences
Enzychem Lifesciences Corp. is a global pharmaceutical company focused on developing oral small molecule therapies for patients with unmet medical needs in the areas of oncology, metabolic diseases and inflammatory diseases. Established in 1999 as a proprietary association, EC-18 is the subject of two Phase 2 clinical trials in chemotherapy-induced oral mucositis and COVID-19. EC-18 acts as an immunomodulator and facilitates the resolution of inflammation and the early return to homeostasis. More information is available at www.enzychem.com.
Investors / business development
Business Development Manager
SOURCE Enzychem Lifesciences